LAUSR

REFERENCES 1. Westin JR, Saliba RM, De Lima M, et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol. 2011;2011:601953-601958. 2. MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol. 2012; 157(6):732-741. 3. Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for glucocorticoidrefractory acute graft-versus-host disease. N Engl J Med. 2020;382(19): 1800-1810. 4. Bilinski J, Lis K, Tomaszewska A, et al. Fecal microbiota transplantation in patients with acute and chronic graft-versus-host disease-spectrum of responses and safety profile. Results from a prospective, multicenter study. Am J Hematol. 2020;96:88-91. 5. Schoemans HM, Lee SJ, Ferrara JL, EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the EBMT NIH (National Institutes of Health) CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graftversus-host disease assessment. Bone Marrow Transplant. 2018; 53(11):1401-1415. 6. https://clinicaltrials.gov/ct2/show/NCT04269850